Group 1: Hong Kong IPO Market Outlook - PwC forecasts that Hong Kong's IPO fundraising could reach between HKD 320 billion to HKD 350 billion in 2026, with around 150 companies expected to list [1] - The number of companies raising over HKD 5 billion is anticipated to exceed 10, driven by declining interest rates and supportive government policies [1] - The trend of A-share companies seeking international fundraising through Hong Kong's capital market is expected to continue [1] Group 2: TVB Management Changes - TVB announced that Eric Tsang will transition from his role as General Manager to the newly established position of Chairman of the Advisory Committee, focusing on new content strategies [2] - This change allows Tsang to concentrate on content innovation and strategic partnerships, potentially enhancing TVB's competitive edge in content creation [2] Group 3: Performance of Hong Kong Stocks - A total of 385 Hong Kong stocks recorded over 100% gains in 2025, with 14 stocks increasing more than tenfold [3] - The top performer, Base Jinbiao Group, saw a 41.64 times increase, while Beihai Kangcheng-B, a biotech firm, surged over 18 times, indicating a high-risk appetite for innovative sectors [3] - The expansion of "red chip" stocks, particularly among newly listed companies, reflects significant liquidity improvements in the Hong Kong market [3] Group 4: Tianxiaxiu's IPO Submission - Tianxiaxiu has submitted its application to the Hong Kong Stock Exchange, positioning itself as China's first mature influencer marketing solutions platform [4] - The company leverages AI, data, and algorithms to connect advertisers with influencers and UGC platforms, aiming to enhance marketing efficiency and commercial monetization [4] Group 5: Hong Kong Stock Market Indices - As of January 5, the Hang Seng Index stood at 26,347.24, with a slight increase of 0.03%, while the Hang Seng Tech Index rose by 0.09% to 5,741.63 [5] - The National Enterprises Index decreased by 0.22%, closing at 9,148.47 [5]

香港聯合交易所有限公司及證券及期貨事務監察委員會對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或依賴該等內 容而引致的任何損失承擔任何責任。 Hangzhou Diagens Biotechnology Co., Ltd. 杭州德適生物科技股份有限公司 警告 本公告乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員 會（「證監會」）的要求而刊發，僅用作向香港公眾人士提供資料。 閣下閱覽本公 告，即表示 閣下知悉、接納並向杭州德適生物科技股份有限公司（「本公司」）、 其獨家保薦人、保薦人兼整體協調人、整體協調人、顧問或包銷團成員表示同 意： 1 (a) 在聯交所網站登載本公告，並不會引致本公司、其獨家保薦人、保薦人兼整 體協調人、整體協調人、顧問或包銷團成員須於香港或任何其他司法權區進 行發售或配售活動的責任。本公司最終會否進行任何發售或配售仍屬未知之 數； (b) 本公告所涉及的上市申請並未獲批准，聯交所及證監會或會接納、發回或拒 絕有關的公開發售及╱或上市申請； (c) 本公告不得被視為勸誘認購或購買任何證券，亦不擬構成該等勸誘； ...

Core Viewpoint - Hong Kong's innovation and technology ecosystem is thriving, marked by significant advancements such as the launch of the "Lion Rock Chip," which represents a breakthrough in local chip design and development [2][3][4]. Group 1: Company Developments - The "Lion Rock Chip," the world's first data center management chip based on RISC-V architecture, has garnered positive market responses, with numerous OEMs, ODMs, and cloud service providers establishing close ties with the company [2]. - The CEO of Sifang Technology, Xu Tao, highlighted the successful trial production of the chip, attributing it to the team's deep technical understanding and rigorous quality control [4]. - Sifang Technology has evolved into a leading enterprise in the RISC-V ecosystem, supported by early investments from Ascend Capital, which recognized the potential of the chip industry seven years ago [3]. Group 2: Ecosystem and Policy Support - The Hong Kong government has actively invested in innovation and technology, with local R&D expenditure projected to rise by 8.4% to HKD 35.772 billion in 2024, increasing its GDP ratio from 1.11% in 2023 to 1.13% [6]. - Over 40 funding programs have been launched by the government to support enterprises in areas such as funding, technology development, and market expansion, contributing to a surge in the number of startups from approximately 1,000 a decade ago to nearly 4,700 in 2024 [8]. - The establishment of the Hong Kong Science Park and the opening of the He Tao Hong Kong Innovation and Technology Park have attracted over 60 companies, further enhancing the local innovation landscape [8]. Group 3: Strategic Positioning - Hong Kong is positioned as a strategic hub that connects international intelligence, capital, and regulations with the robust industrial and market arteries of mainland China, facilitating the transformation of research outcomes into commercial applications [11][12]. - The "14th Five-Year Plan" emphasizes Hong Kong's role in building an international innovation and technology center, with the government committed to accelerating the development of innovation and technology as a key economic driver [12].

市场每天都有几十只个股涨停，但未必都是机会。 龙虎榜是"明牌"，席位背后的关联性是"暗牌"。跟踪席位能让你看清是谁在主导行情，是机构在调仓， 还是游资在对倒出货。 龙虎榜不是拿来"跟买"的，而是拿来"拆解"的。知名席位上榜，自带吸粉效应，次日开盘往往有更高的 溢价。游资席位的分布能帮你分辨谁是"虫"，谁是"真龙"。 板块热度 A股今日喜迎2026年开门红，沪指12连阳，重新站上4000点大关。沪深两市成交额达到25675亿元，较 上一个交易日大幅放量5016亿元。行业板块呈现普涨态势，上涨股票数量接近4200只，近130只股票涨 停。 人脑工程概念股集体爆发，博拓生物、三博脑科等多只股票20cm涨停。脑机接口概念股飙涨，或与马 斯克近日重磅宣布的脑机接口设备"量产预告"有关。做投资就是要找那种能够改变时代的重大题材，那 种可以引领人类社会科技进步的题材。 龙虎榜主力动向 1、消闲派携手"章盟主"席位封板航天机电 消闲派是A股新生代游资中的标杆性人物，以稳健型超短著称，从20万起步到身家数亿，6年最大回撤 仅10%，其交易风格兼具快准狠的短线特质与稳如磐石的风控意识，核心风格可概括为"以首板为锚、 以情绪为核、 ...

Group 1 - Aktis Oncology Inc. plans to conduct an initial public offering (IPO) in the United States, aiming to raise up to $212 million [1] - The company intends to issue 11.8 million shares at a price range of $16 to $18 per share, potentially valuing the company at approximately $840 million [1] - Aktis specializes in developing alpha particle radiotherapy for solid tumors and was founded in 2021 [1] Group 2 - For the nine months ending September 30, the company reported revenues of $4.6 million and a net loss of $48.6 million, compared to revenues of $554,000 and a net loss of $31.9 million in the same period the previous year [1] - Aktis has raised approximately $346 million from top life sciences investors, including MPM, Vida, EcoR1 Capital, and Blue Owl Capital [2] - The IPO will be led by JPMorgan, Bank of America, Leerink Partners, and TD Securities, with plans to list on the NASDAQ under the ticker symbol AKTS [2]

【德适生物港股IPO获中国证监会备案】智通财经1月5日电，证监会国际合作司发布杭州德适生物科技 股份有限公司境外发行上市及境内未上市股份"全流通"备案通知书，公司拟发行不超过31,004,000股境 外上市普通股并在香港联合交易所上市。 转自：智通财经 ...

Core Viewpoint - The company Shuoshi Biotechnology (688399) has received a government subsidy of 1.63 million RMB, which will impact its financial results for the fiscal year 2025 [1]. Group 1: Stock Performance - As of January 5, 2026, the stock closed at 68.88 RMB, up 0.55% from the previous trading day [1]. - The stock opened at 68.51 RMB, reached a high of 69.14 RMB, and a low of 67.97 RMB, with a trading volume of 96.52 million RMB and a turnover rate of 1.68% [1]. Group 2: Government Subsidy - The company announced it received a government subsidy of 1.63 million RMB, categorized as a revenue-related government grant [1]. - The accounting treatment and impact of this subsidy on the company's financials will be confirmed by the annual audit results [1]. - The board of directors has assured the accuracy and completeness of the announcement regarding the subsidy [1].

Group 1 - The core viewpoint of the news is that Brain Rejuvenation Technology (RGC.US) stock surged nearly 44% in pre-market trading, driven by the excitement around brain-computer interface technologies, particularly following Elon Musk's production forecast [1] - The relationship between Brain Rejuvenation Technology and brain-computer interfaces can be understood as an upstream and downstream connection in the medical field, where "repairing hardware" and "establishing connections" are interlinked [1] - The surge in interest for brain-computer interfaces has led to a chain reaction effect, benefiting related technologies like brain rejuvenation due to their shared narrative of "brain technology" [1] Group 2 - RGC's pre-market price reached $29.550, reflecting a 43.87% increase, while the closing price was $20.540, down 2.19% [2] - The stock's trading volume was 200,600 shares, with a market capitalization of $10.157 billion [2] - The stock has a 52-week high of $83.600 and a low of $0.093, indicating significant volatility in its price history [2]

Group 1 - The core viewpoint of the articles emphasizes the continuous optimization of private investment structure, showcasing a trend towards practical and innovative investments, particularly in infrastructure [1] - Private investment in infrastructure steadily increased, with a year-on-year growth of 3.5% from January to November 2025, including significant growth in water management (34.2%) and air transport (25.1%) [1] - The scale of special long-term government bonds is projected to reach 1.3 trillion yuan in 2025, a substantial increase of 800 billion yuan compared to 2024, with funds allocated to support major projects and policies [1] Group 2 - By the end of November 2025, the total social financing scale reached 440.07 trillion yuan, with a year-on-year increase of 6.3% in loans to the real economy [2] - The banking sector saw a year-on-year growth of 2.1% in loans to small and micro enterprises, indicating a supportive financial environment for private investment [2] - The implementation of a moderately loose monetary policy in 2026 aims to accelerate financial supply-side structural reforms [2] Group 3 - Private investment is identified as a crucial support for stabilizing growth, adjusting structure, and promoting employment, with expectations for more proactive macro policies to stimulate private investment vitality [3] - The dialogue with private entrepreneurs and financial professionals highlights the need for macro policies to better support private enterprises in expanding investments [3] Group 4 - A case study of a small motorcycle export enterprise illustrates the effectiveness of tailored financial services, resulting in a 30% year-on-year increase in sales due to timely financing support [4] - The establishment of a coordinated financial service mechanism has led to significant credit support for small and micro enterprises, with a total of 7.68189 trillion yuan in loans disbursed by November 2025 [5] Group 5 - Financial institutions are encouraged to develop financing products that meet the needs of private investments, enhancing the resilience of the industrial system by supporting key industry chains [6] - The focus on modern industrial system construction aims to direct financial resources towards weak links in industry chains, promoting overall industrial development [6] Group 6 - Companies are increasingly recognizing the importance of government policies in supporting private investment, with examples of successful collaborations between enterprises and financial institutions leading to significant growth [8][10] - The emphasis on long-term stable financial support is crucial for small and micro enterprises to focus on quality control and investment [18]

Group 1 - The core viewpoint of the news is the performance and financial status of Beijing Baipusi Biotechnology Co., Ltd., which saw a stock price increase of 5.07% to 56.74 CNY per share, with a total market capitalization of 9.486 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with its main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] Group 2 - From the perspective of fund holdings, Guotai Fund has a significant position in Baipusi, with the Guotai Innovation Medical Mixed Fund A (018159) holding 21,600 shares, representing 5.2% of the fund's net value, making it the seventh-largest holding [2] - The Guotai Innovation Medical Mixed Fund A was established on April 18, 2023, with a latest scale of 17.7778 million CNY, and has achieved a year-to-date return of 38.09%, ranking 2210 out of 8155 in its category [2] Group 3 - The fund manager of Guotai Innovation Medical Mixed Fund A is Qiu Xiaoxu, who has been in the position for 3 years and 144 days, managing assets totaling 676 million CNY, with the best fund return during the tenure being 5.58% and the worst being 0.5% [3]